

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Dale M. Edgar, David G. Hangauer, Harry Jefferson Leighton, and
Emmanual J. M. Mignot

Continuation Application of

Application No.: 10/272,510

Filed: October 16, 2002

For: CNS Target Modulators

Date: 12/4/03

EXPRESS MAIL LABEL NO. EV215729913US

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)

under 37 CFR 1.97(b), or

(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

under 37 CFR 1.97(c) together with either:

a Statement under 37 CFR 1.97(e), as checked below, or

a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

under 37 CFR 1.97(d) together with:

a Statement under 37 CFR 1.97(e), as checked below, and

a \$180.00 fee under 37 CFR 1.17(p), or

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

Enclosed herewith is form PTO-1449:

Copies of the cited references are enclosed.

Since this application was filed after June 30, 2003, copies of issued U.S. patents and published U.S. applications are not required and are not being provided.

Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. 10/272,510, to which priority under 35 U.S.C. 120 is claimed. The earlier application contains copies of the cited references.

The listed references were cited in the enclosed International Search Report in a counterpart foreign application.

The "concise explanation" requirement (non-English references) for reference AO under 37 CFR 1.98(a)(3) is satisfied by:

the explanation provided on the attached sheet.

the explanation provided in the Specification.

submission of the enclosed International Search Report entered in prior application, U.S. Application No. 10/272,510.

submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.

the English language abstract, (1991 : 655997 HCAPLUS), entered in prior application, U.S. Application No. 10/272,510.

Applicant requests that the following non-published pending applications be considered:

Examiner's
Initials

U.S. Patent Application No. 10/272,510, by Dale M. Edgar, David G. Hangauer, Harry Jefferson Leighton and Emmanuel J. M. Mignot, filed October 16, 2002, Docket No.: 3561.1000-004.

U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

Examiner

Date

A copy of each above-cited application, including the current claims, is enclosed.

A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.

Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.

Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By

Steven G. Davis

Registration No.: 39,652

Telephone: (978) 341-0036

Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated:

December 4 2003

PTO-1449 REPRODUCED			ATTORNEY DOCKET NO. 3561.1000-007	CONTINUATION APPLICATION OF 10/272,510	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			APPLICANT Dale M. Edgar		
December 4, 2003 (Use several sheets if necessary)			FILING DATE December 4, 2003	CONFIRMATION NO.	GROUP

U.S. PATENT DOCUMENTS					
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME	
	AA	5,095,022	10-MAR-92	Ito et al.	
	AB	6,391,890	21-MAY-02	Jorgensen et al.	
	AC	5,153,207	06-OCT-92	Ito, et al.	
	AD	4,929,618	29-MAY-90	Koda, et al.	
	AE	6,358,944 B1	19-MAR-02	Lederman, et al.	
	AF	6,387,930 B1	14-MAY-02	Baroudy, et al.	
	AG				
	AH				
	AI				
	AJ				
	AK				
	AA2				
	AB2				
	AC2				
	AD2				
	AE2				
	AF2				
	AG2				
	AH2				
	AI2				
	AJ2				
	AK2				
	AA3				
	AB3				
	AC3				

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION December 4, 2003 (Use several sheets if necessary)		ATTORNEY DOCKET NO. 3561.1000-007	CONTINUATION APPLICATION OF 10/272,510
		APPLICANT Dale M. Edgar	
		FILING DATE December 4, 2003	CONFIRMATION NO.
			GROUP

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
AL		WO 99/00376 A1	07-JAN-99	PCT	
AM		EP 0 406 739 A2	09-JAN-91	EPO	
AN		WO 88/09656	15-DEC-88	PCT	
AO		JP 03133956	07-JUN-91	Japan	X
AP					
AQ					
AL2					
AM2					
AN2					
AO2					
AP2					
AQ2					
AL3					
AM3					
AN3					
AO3					
AP3					
AQ3					
AL4					
AM4					
AN4					
AO4					
AP4					
AQ4					
AL5					
AM5					

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION December 4, 2003 (Use several sheets if necessary)		ATTORNEY DOCKET NO. 3561.1000-007	CONTINUATION APPLICATION OF 10/272,510	
		APPLICANT Dale M. Edgar		
		FILING DATE December 4, 2003	CONFIRMATION NO.	GROUP

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AR	Iwasaki, N., et al., "Amphoteric Drugs. II. ¹⁾ Synthesis and Antiallergic Activity of [4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)piperidino]alkanoic Acid Derivatives and Related Compounds," <i>Chem Pharm Bull</i> , 42(11):2285-2290 (1994).
AS	Iwasaki, et al., "Amphoteric drugs. I. Synthesis and antiallergic activity of [4- (diphenylmethoxy) piperidino] -, [4- (diphenylmethyl) piperazinyl] - and [4- (diphenylmethylene) piperidino] alkanoic acid derivatives," <i>Chemical & Pharmaceutical Bulletin</i> , 42(11): 2276-2284 (1994) . Abstract Accession #: 1995: 441018 HCAPLUS.
AT	Iwasaki, N., et al., "Amphoteric Drugs. I. Synthesis and Antiallergic Activity of [4- (Diphenylmethoxy)piperidino]-, [4(Diphenylmethyl)piperazinyl]- and [4-(Diphenylmethylene) piperidino]alkanoic Acid Derivatives," <i>Chem. Pharm. Bull.</i> , 42(11): 2276-2284 (1994).
AU	
AV	
AW	
AX	
AY	
AZ	
AR2	
AS2	
AT2	
AU2	
AV2	
AW2	

EXAMINER	DATE CONSIDERED
----------	-----------------